Healthcare / Medical Instruments & SuppliesWarsaw
$0.28
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-4.2M · quality 60.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$32M
P/E
13.8x
↓EV/EBITDA
11.1x
↓ROE
-20.5%
↓Gross Margin
-1125.0%
↓Debt/Equity
-1.51
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-65.2%
FCF CAGR
—
FCF margin
-90475.0%
FCF / Net income
-2.07x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4000.0 · net income $1.7M · FCF $-3.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4000.00 | $4000.00 | $12000.00 | $12000.00 | $95000.00 |
| Net Income | $1.7M | $1.7M | $-11.7M | $-3.3M | $-37.9M |
| EBITDA | $3.5M | $3.5M | $-10.9M | $-1.2M | $-36.0M |
| EPS | 0.02 | 0.02 | -0.16 | -0.05 | -0.65 |
| Gross Margin | -1125.0% | -1125.0% | -50.0% | 100.0% | 100.0% |
| Operating Margin | -147775.0% | -147775.0% | -42358.3% | -20741.7% | -2912.6% |
| Net Margin | 43650.0% | 43650.0% | -97791.7% | -27300.0% | -39909.5% |
| Balance Sheet | |||||
| Debt/Equity | -1.51 | -1.51 | -0.90 | -1.10 | -0.96 |
| Current Ratio | 0.07 | 0.07 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-3.6M | $-3.6M | $-7.6M | $-4.2M | $-572000.00 |
| Returns | |||||
| ROE | -20.5% | -20.5% | 48.3% | 24.8% | 250.1% |
| Valuation | |||||
| P/E | 13.78 | 13.78 | — | — | — |
| EV/EBITDA | 11.06 | 11.06 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | -66.7% | -66.7% | 0.0% | -87.4% | — |
| EPS Growth | 112.5% | 112.5% | -220.0% | 92.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
6.9%
EPS terminal req.
$0.02
Spread vs growth
105.6%
5Y implied EPS CAGR
8.1%
EPS terminal req.
$0.03
Spread vs growth
104.4%
10Y implied EPS CAGR
9.1%
EPS terminal req.
$0.05
Spread vs growth
103.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-23.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.16 → 0.02
Residual
-23.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.